119th Congress · introduced in the Senate · Jul 15, 2026
Cancer Drug Parity Act of 2026
Official title from Congress.gov
Latest action (Jul 15, 2026): Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
View on Congress.govPolicy area: Health
No official summary has been published for this bill.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Actions from Congress.gov, newest first.
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 23, 2026.
2 citations.
THE SUSAN G. KOMEN BREAST CANCER FOUNDATION, INC. DBA SUSAN G. KOMEN · lobbying firm or registrant: THE SUSAN G. KOMEN BREAST CANCER FOUNDATION, INC. DBA SUSAN G. KOMEN
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 23, 2026 · issue area: Insurance
$70,000
Spent on own lobbying
…Diagnosis Act; a bill to eliminate cost sharing for medically necessary diagnostic and supplemental breast imaging for patients with private insurance H.R.4101/S.5004 - Cancer Drug Parity Act; a bill to amend the Employee Retirement Income Security Act of 1974 to require a group health plan (or health insurance coverage offe…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
HEMATOLOGY ONCOLOGY PHARMACY ASSOCIATION · lobbying firm or registrant: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 7, 2026 · issue area: Health Issues
$50,000
Paid to lobbying firm
Cancer Drug Parity Act (H.R. 4101 / S. 5004); Improving Seniors' Timely Access to Care Act (H.R. 3514 / S. 1816); Drug Shortages
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing